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A B S T R A C T
Between January 1999 and June 2002, 646 invasive
isolates of Streptococcus pneumoniae were collected
in Ireland. MICs of penicillin, ciprofloxacin, cefo-
taxime, moxifloxacin and linezolid were deter-
mined by Etest methodology. Eighty-seven
(13.5%) isolates showed intermediate resistance
to penicillin, while seven (1.1%) showed high-
level resistance. Eighty-seven (13.5%) isolates
were resistant to erythromycin, but all isolates
were susceptible to cefotaxime, moxifloxacin and
linezolid. The prevalence of pneumococcal iso-
lates non-susceptible to penicillin in Ireland is
worryingly high, but currently there are alternat-
ive agents available to treat invasive infection.
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Streptococcus pneumoniae is a significant cause of
bacteraemia and meningitis. In a recent UK study,
the annual population incidence of bacteraemia
was 9.8 ⁄ 100 000, with a mortality rate of 24% [1].
Increasingly, pneumococcal isolates are resist-
ant to penicillin. The prevalence of non-
susceptibility to penicillin in the UK increased
from 1.5% in 1990 to 3.9% in 1995 [2], while in
Quebec, Canada, the prevalence changed from
11% to 12% from 1996 to 1998 [3]. However,
antibiotic resistance may not always correlate
directly with an adverse outcome. Thus, a study
comparing 22 meningitis patients from whom
cefotaxime-non-susceptible pneumococcal iso-
lates were obtained with 87 patients from whom
cefotaxime-susceptible isolates were obtained
revealed no difference in mortality or length of
hospital stay [4].
The present study examined the susceptibility
to newer antimicrobials of 646 invasive isolates of
pneumococci, i.e., from blood (620 isolates) or
cerebrospinal fluid (26 isolates), collected as part
of the European Antimicrobial Resistance Surveil-
lance System (EARSS). Isolates were submitted by
referring laboratories participating in the EARSS
project for further susceptibility testing between
January 1999 and the end of June 2002. All isolates
were tested for penicillin susceptibility by routine
disk diffusion with an oxacillin disk (1 lg), and for
erythromycin susceptibility according to the Brit-
ish Society for Antimicrobial Chemotherapy
guidelines [5]. ATCC strains 49619 and 6306 were
used as controls. MICs of penicillin, cefotaxime
and ciprofloxacin were determined by Etests (AB
Biodisk, Solna, Sweden) according to the manu-
facturer’s instructions. In addition, MICs of mox-
ifloxacin and linezolid were determined by Etest
for 288 and 340 isolates, respectively. All plates
were incubated in CO2 5–10% v ⁄ v for 24 h at 37C.
The 646 isolates were obtained from patients
with a mean age of 50.8 years; 14.5% of the
isolates were from patients aged £ 4 years, and
42.9% from patients aged ‡ 65 years. The male:
female ratio was 1.18:1; 47% of patients were from
general medical wards and 7% were from paedi-
atric wards. Of the isolates tested, 94 (14.6%) were
non-susceptible to penicillin, of which 87 (13.5%)
showed intermediate resistance, i.e., with an MIC
of 0.1–1 mg ⁄L, while seven (1.1%) isolates
showed high-level resistance, i.e., with an MIC
of 2 mg ⁄L (Fig. 1). Eighty-seven (13.5%) isolates
were resistant to erythromycin, of which 62
(71%), 21 (25%) and four (4%) were susceptible,
intermediately or highly resistant, respectively, to
penicillin. All isolates had a cefotaxime MIC
£ 1.0 mg ⁄L, i.e., were susceptible. All but one
isolate (MIC 4 mg ⁄L) had a ciprofloxacin MIC
< 4 mg ⁄L. The MIC90 of moxifloxacin was
0.094 mg ⁄L, and no isolate had an MIC
> 1.0 mg ⁄L; therefore, all isolates were suscept-
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ible. The MIC90 of linezolid was 0.5 mg ⁄L, and no
isolate had an MIC > 1.0 mg ⁄L; therefore, all
isolates were susceptible (Fig. 1).
The prevalence of isolates non-susceptible to
penicillin among invasive strains of pneumococci
is high in Ireland compared with many European
countries [6,7]. The prevalence given in the
EARSS data for 2002 is 11.5%, which is higher
than in the UK (4.7%), The Netherlands (1.2%)
and Germany (1.3%), but lower than in Spain
(33.3%) and Portugal (19.7%) [6].
Overall, 13.5% of the isolates in the present
study were resistant to erythromycin. In a study of
2586 invasive isolates from Germany, only 7.7% of
isolates were resistant to erythromycin; of these,
12.1% were either intermediately or highly resist-
ant to penicillin [8], compared with 29% in the
present study. All isolates (100%) in the present
study were susceptible to cefotaxime
(MIC £ 1.0 mg ⁄L), compared with 99.7% of the
German isolates [8], but the German study was
considerably larger. Of Irish pneumococcal iso-
lates recovered from patients with lower respirat-
ory tract infections between 1997 and 1998, 23%
were either intermediately or fully resistant to
cefotaxime according to the then British Society for
Antimicrobial Chemotherapy guidelines, but the
MIC90 was 1 mg ⁄L [9]. However, these were non-
invasive isolates, and non-susceptibility to cefo-
taxime may reflect exposure to previous antibiotics
in patients with chronic pulmonary disease.
None of the present isolates had a ciprofloxacin
MIC > 4 mg ⁄L, a breakpoint used previously [10].
One isolate had an MIC of 4 mg ⁄L; i.e., it was
resistant according to British Society for Antimi-
crobial Chemotherapy interpretive criteria [5]
(there are no breakpoints provided by the National
Committee for Clinical Laboratory Standards). In
the USA, only 0.3% of isolates had a ciprofloxacin
MIC ‡ 4 mg ⁄L [10]. Many guidelines for the
treatment of respiratory infection now include
fluoroquinolones such as moxifloxacin. Only 0.9%
of 807 isolates from sterile sites were resistant to
moxifloxacin in a recent UK study; 8% were non-
susceptible to penicillin, but 99%were resistant to
ciprofloxacin, with a breakpoint of 1 mg ⁄L [11].
All of the present isolates had a moxifloxacin MIC
< 1 mg ⁄L, i.e., were susceptible. However, multi-
drug-resistant clones are prevalent in Hong Kong
and Spain [12], and these could spread to Ireland.
Linezolid has an anti-Gram-positive bacterial
spectrum, with little or no cross-resistance
to other agents [13]. In a UK study of 374
Gram-positive isolates, the linezolid MICs were
0.5–2 mg ⁄L for all except the enterococci; all
pneumococci (41 isolates) had an MIC of either
1 or 2 mg ⁄L [14]. With a breakpoint of 4 mg ⁄L, all
isolates (including those in the present study)
were susceptible to linezolid.
Invasive infection can be prevented by vaccin-
ation. Irish EARSS isolates from 1999 comprised
25 capsular serotypes, with serotypes 14 (20.8%),
0
10
20
30
40
50
60
70
80
90
%
0.
01
6
0.
03
2
0.
06
4
0.
12
5
0.
25
0
0.
50
0
1.
00
0
2.
00
0
4.
00
0
8.
00
0
Linezolid MIC
0
10
20
30
40
50
60
70
80
90
%
0.
00
2
0.
00
4
0.
00
8
0.
01
6
0.
03
2
0.
06
4
0.
12
5
0.
25
0
0.
50
0
1.
00
0
2.
00
0
4.
00
0
Cefotaxime MIC
0
10
20
30
40
50
60
70
80
90
%
0.
00
2
0.
00
4
0.
00
8
0.
01
6
0.
32
0
0.
64
0
0.
12
5
0.
25
0
0.
50
0
1.
00
0
2.
00
0
Moxifloxacin MIC
0
10
20
30
40
50
60
70
80
90
%
0.
01
6
0.
03
2
0.
06
4
0.
12
5
0.
25
0
0.
50
0
1.
00
0
2.
00
0
4.
00
0
Penicillin MIC
Breakpoints
Breakpoint
Breakpoint
Breakpoint
Fig. 1. Distribution of MICs (deter-
mined according to British Society
for Antimicrobial Chemotherapy
guidelines and breakpoints) of peni-
cillin, cefotaxime, moxifloxacin and
linezolid among invasive isolates of
Streptococcus pneumoniae in Ireland
between 1999 and 2002.
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9V (15.3%), 4 (9%), 3 (6.9%), 8 (5.6%), 12B (4.9%)
and 5 (4.9%) being the most common [15]. Only
four serotypes were represented among the peni-
cillin-non-susceptible isolates, namely 9V (74%),
14 (14.8%), 23F (7.4%) and 6B (3.7%). Only 11%
of all isolates belonged to serotypes not included
in the 23-valent non-conjugated polysaccharide
vaccine, but some protection may be afforded by
cross-reactivity between serotypes [15].
In conclusion, the prevalence of isolates non-
susceptible to penicillin in Ireland is worryingly
high, but all isolates are currently susceptible to
cefotaxime, moxifloxacin and linezolid. Patients
in Ireland with invasive pneumococcal infections
should continue to receive cefotaxime as empir-
ical treatment. Should cefotaxime resistance
emerge, the extended-spectrum fluoroquinolones
and linezolid may be useful alternatives.
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A B S T R A C T
An isolate of Streptococcus pyogenes isolated from a
63-year-old woman with a serious wound infection
wasfoundtobehighlyresistant tofluoroquinolones
(levofloxacin MIC ‡ 32 mg ⁄L). DNA amplification
and sequencing revealed a serine-81 to phenylalan-
ine substitution in gyrA and three substitutions in
parC: serine-79 to phenylalanine, aspartic acid-91 to
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